Ratings Rapid Micro Biosystems, Inc.

Equities

RPID

US75340L1044

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-16 pm EDT			5-day change	1st Jan Change
0.82 ^USD	+1.25%		+1.86%	+10.81%

May. 03	Transcript : Rapid Micro Biosystems, Inc., Q1 2024 Earnings Call, May 03, 2024
May. 03	Earnings Flash (RPID) RAPID MICRO BIOSYSTEMS Posts Q1 Revenue $5.6M	MT

Summary

According to Refinitiv, the company's ESG score for its industry is poor.

Strengths

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
Thanks to a sound financial situation, the firm has significant leeway for investment.
The company appears to be poorly valued given its net asset value.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
RAPID MICRO BIOSYSTEMS, INC.	+10.81%	35.09M	C-
ELI LILLY AND COMPANY	+32.36%	694B	C+
NOVO NORDISK A/S	+29.59%	593B	B
JOHNSON & JOHNSON	-1.60%	371B	C+
MERCK & CO., INC.	+20.07%	331B	B-
ABBVIE INC.	+6.04%	290B	C+
ASTRAZENECA PLC	+14.51%	239B	B+
ROCHE HOLDING AG	-3.48%	209B	A+
NOVARTIS AG	+10.07%	209B	B-
AMGEN INC.	+9.27%	169B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes